IRVINE, Calif., May 2, 2018 /PRNewswire/ — Johnson & Johnson Medical Devices Companies* announced today that Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of heart arrhythmias, has enrolled and treated the first patient in its QDOT AF Study.** The study will evaluate the delivery of high power, short duration ablation […]
Other News
CardioFocus® Announces FDA Approval Of The Next-Generation HeartLight® Excalibur Balloon™ Designed For The Treatment Of Paroxysmal Atrial Fibrillation*
MARLBOROUGH, Mass., May 7, 2018 /PRNewswire/ — CardioFocus, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted approval for the HeartLight Excalibur Balloon, a next-generation technology designed for the treatment of paroxysmal atrial fibrillation (PAF)*. The Excalibur Balloon leverages the proven universal balloon design of the company’s FDA-approved HeartLight® Endoscopic Ablation System and introduces an […]
THEROX COMPLETES FINANCING AS IT PREPARES FOR AMI THERAPY SYSTEM LAUNCH
Supports U.S. Market Introduction of SuperSaturated Oxygen Therapy for Improved AMI Patient Outcomes Irvine, Calif., May 7, 2018 – TherOx®, a privately held medical device company focused on improving treatment of acute myocardial infarction (AMI), today announced completion of a debt financing for an undisclosed amount led by existing investor […]
Heart Sciences announces that Professor Peter McFarlane has been appointed to the clinical advisory committee
Southwest Texas South Lake – ( BUSINESS WIRE ) – ( BUSINESS WIRE ) – As a US-based medical equipment company, continuous wavelet transform (CWT) signal processing method and field of electrocardiogram inspection through application of artificial intelligence to lead the innovation in the heart Sciences today announced that it has welcomed Peter · W · McFarlane […]
Jeffrey S. Borer, MD, Recognized for Achievements in Cardiology
NEW YORK, May 4, 2018 /PRNewswire/ — Jeffrey S. Borer, MD, is a distinguished biographee of Marquis Who’s Who. As in all Marquis Who’s Who biographical volumes, individuals profiled are chosen from among a pool of the most prominent professionals and are selected on the basis of current reference value. Factors such as […]
Endologix Appoints John Onopchenko as Chief Executive Officer
IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed John Onopchenko as the Company’s Chief Executive Officer, effective immediately. Dan Lemaitre, Chairman of the Board of Directors of Endologix, Inc., commented, “We are very pleased to welcome […]
BD Announces Results For 2018 Second Fiscal Quarter; Raises Fiscal 2018 Guidance
FRANKLIN LAKES, N.J., May 3, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.222 billion for the second fiscal quarter ended March 31, 2018. This represents an increase of 42.2 percent from the prior-year period, which is primarily due to the acquisition […]
Cardiac Insight, Inc. to Showcase Industry-First Cardiac Devices for Atrial Fibrillation and Sudden Cardiac Arrest Risk Detection at Heart Rhythm 2018, Heart Rhythm Society’s 39th Annual Scientific Sessions, May 9-11, Exhibit 1071
KIRKLAND, Wash.–(BUSINESS WIRE)–Cardiac Insight, Inc., a leading U.S. developer of wearable cardiac medical devices and diagnostic software systems with proprietary algorithms, announced today the company will showcase its innovative solutions for the first time at Heart Rhythm Society’s 39th Annual Scientific Sessions. Heart Rhythm 2018 will be held May 9-11, 2018 […]
Eidos Therapeutics Initiates Phase 2 Clinical Trial for AG10 Targeting Transthyretin Amyloidosis Cardiomyopathy
SAN FRANCISCO, May 3, 2018 /PRNewswire/ — Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company developing a novel oral therapy to treat transthyretin (TTR) amyloidosis (ATTR), today announced dosing of the first patient in the Phase 2 clinical trial of AG10 in patients with ATTR cardiomyopathy (NCT03458130). The Phase 2 trial will enroll […]
Cardiovascular Systems (CSII) Q3 Earnings Top, Revenues Meet
Cardiovascular Systems, Inc. CSIIreported earnings per share of a penny in third-quarter fiscal 2018 against the year-ago quarterly loss of 5 cents. The figure remained ahead of the earlier guided range of a loss of 3 cents to breakeven. Moreover, the bottom line compared favorably with the Zacks Consensus Estimate of […]



